Showing results (221-230 of 353) with videos related to
Sort By:
Pageof 36
Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.Blood Advances|July 6, 2022
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysisDanny Luan, Tolulope Fatola, Ahmed Toure, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 1999
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignanciesJ W Friedberg, D Neuberg, J G Gribben, et al.British Journal of Haematology|April 23, 2014
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433Jonathan W Friedberg, Joseph M Unger, W Richard Burack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyCarla Casulo, Michelle Byrtek, Keith L Dawson, et al.Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.Leukemia & Lymphoma|December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacyAjay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotectionGordon L Phillips, Steven H Bernstein, Jane L Liesveld, et al.Pageof 36